oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Publications (4 of 4) Show all publications
Jansson, S. P. O., Engfeldt, P., Magnuson, A., Lohse PT, G. & Liljegren, G. (2013). Interventions for lifestyle changes to promote weight reduction, a randomized controlled trial in primary health care. BMC Research Notes, 16(1), Article ID 213.
Open this publication in new window or tab >>Interventions for lifestyle changes to promote weight reduction, a randomized controlled trial in primary health care
Show others...
2013 (English)In: BMC Research Notes, ISSN 1756-0500, E-ISSN 1756-0500, Vol. 16, no 1, article id 213Article in journal (Refereed) Published
Abstract [en]

Background: Overweight and obesity are growing public health problems in high income countries and is now growing at a dramatic pace in low and middle income countries, particularly in urban settings. The aim of this trial was to examine the effects of a weight reduction program in adults and to determine whether or not a more extensive intervention was superior to ordinary care.

Methods: Patients seeking advice for overweight/obesity or illness related to overweight/obesity at eight primary health care centers in Sweden were randomized either to intervention or control care groups with both groups given dietary advice and individualized information on increased regular physical activity. In the intervention group advice was more extensive and follow-up more frequent than in the control group during the study period of two years. Main outcome measure was reduction in body weight of five percent or more from study start.

Results: From October 2004 to April 2006, 133 patients, 67 in the intervention group and 66 in the control group, were randomized over a period of 18 months. Target weight was achieved at 12 months by 26.7% of the patients in the intervention group compared with 18.4% in the control group (p = 0.335). There was an average absolute weight loss of 2.5 kg in the intervention group and 0.8 kg in the control group at 12 months as compared with the weight at study entry. There were no significant differences between the groups in quality of life, blood glucose and lipids. At 24 months target weight was achieved in 21.9% versus 15.6%, with an average weight reduction of 1.9 kg and 1.2 kg in the two groups, respectively.

Conclusions: Promotion of a diet with limited energy intake, appropriate composition of food and increased physical activity had limited effects on body weight in a Swedish primary care setting. More extensive advice and more frequent visits made no significant difference to the outcome.

Place, publisher, year, edition, pages
UK: BioMed Central Ltd., 2013
Keywords
Lifestyle changes, Obesity, Weight reduction, Family practice
National Category
Medical and Health Sciences Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
urn:nbn:se:oru:diva-42586 (URN)10.1186/1756-0500-6-213 (DOI)2-s2.0-84878040046 (Scopus ID)
Available from: 2015-02-11 Created: 2015-02-11 Last updated: 2018-05-26Bibliographically approved
Johansson, B., Karlsson, L., Liljegren, G., Hardell, L. & Persliden, J. (2009). Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study. Radiotherapy and Oncology, 90(1), 30-35
Open this publication in new window or tab >>Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study
Show others...
2009 (English)In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 90, no 1, p. 30-35Article in journal (Refereed) Published
Abstract [en]

BACKGROUND AND PURPOSE: To evaluate the long time outcome with regard to local tumour control, cosmetic outcome and side effects of a short (5 days) accelerated interstitial brachytherapy treatment delivered to the surroundings of the operated sector. PATIENTS AND METHODS: Between 1993 and 2003 we treated 50 women with early T1 and T2 breast cancer. Radical sector resection was performed and followed later with an interstitial pulsed dose rate (PDR) brachytherapy of 50Gy in 5 days. The treatment was centred on the tumour with a margin of 30mm. One patient was treated bilaterally. The patients were followed for a median of 86 (32-126) months. RESULTS: Ipsilateral breast cancer recurrence was seen in 3 patients (6%). Two of them occurred outside the treated volume. The 5- and 7-year rates of actuarial local control were 96% and 96%, respectively, overall survival 88% and 85%, disease free survival 88% and 88%, respectively. A dosimetrical analysis showed that the partial breast irradiation covered a median of 31% of the total breast volume. Fat necrosis was seen in 12% and local (moderate-strong) fibrosis in 26% of the patients. Independent cosmetic scoring showed good or excellent result in 56% of the patients. CONCLUSIONS: Local outcome is favourable and very similar to other published studies of accelerated partial breast irradiation. Our long time cosmetic results are lower than other published results.

Place, publisher, year, edition, pages
Amsterdam: Elsevier, 2009
Keywords
Brachytherapy; Pulsed dose rate; Breast cancer; Accelerated partial breast irradiation; Cosmetics; Outcome; Radiotherapy
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-10401 (URN)10.1016/j.radonc.2008.02.022 (DOI)000262958000004 ()18410975 (PubMedID)2-s2.0-58149235035 (Scopus ID)
Available from: 2010-04-20 Created: 2010-04-20 Last updated: 2017-12-12Bibliographically approved
Bergkvist, L., de Boniface, J., Jönsson, P.-E., Ingvar, C., Liljegren, G. & Frisell, J. (2008). Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish Multicenter Cohort Study. Annals of Surgery, 247(1), 150-156
Open this publication in new window or tab >>Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish Multicenter Cohort Study
Show others...
2008 (English)In: Annals of Surgery, ISSN 0003-4932, E-ISSN 1528-1140, Vol. 247, no 1, p. 150-156Article in journal (Refereed) Published
Abstract [en]

Background: Sentinel lymph node biopsy is an established staging method in early breast cancer. After a negative biopsy, most institutions will not perform a completion axillary dissection. The present study reports the current axillary recurrence (AR) rate, overall and disease-free survival in the Swedish Multicenter Cohort Study.

Methods: From 3534 patients with primary breast cancer ≤3 cm prospectively enrolled in the Swedish multicenter cohort study, 2246 with a negative sentinel node biopsy and no further axillary surgery were selected. Follow-up consisted of annual clinical examination and mammography. Twenty-six hospitals and 131 surgeons contributed to patient accrual.

Results: After a median follow-up time of 37 months (0-75), the axilla was the sole initial site of recurrence in 13 patients (13 of 2246, 0.6%). In another 7 patients, axillary relapse occurred after or concurrently with a local recurrence in the breast, and in a further 7 cases, it coincided with distant or extra-axillary lymphatic metastases. Thus, a total of 27 ARs were identified (27 of 2246, 1.2%). The overall 5-year survival was 91.6% and disease-free survival 92.1%.

Conclusions: This is the first report from a national multicenter study that covers, not only highly specialized institutions but also small community hospitals with just a few procedures per year. Despite this heterogeneous background, the results lie well within the range of AR rates published internationally (0%-3.6%). The sentinel node biopsy procedure seems to be safe in a multicenter setting. Nevertheless, long-term follow-up data should be awaited before firm conclusions are drawn.

Keywords
Adult, Aged, Aged; 80 and over, Axilla, Breast Neoplasms/epidemiology/*pathology, Female, Follow-Up Studies, Humans, Incidence, Lymphatic Metastasis, Middle Aged, Neoplasm Recurrence; Local/*epidemiology, Prospective Studies, Risk Factors, Sentinel Lymph Node Biopsy, Survival Analysis, Sweden/epidemiology
National Category
Medical and Health Sciences Surgery Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-3422 (URN)10.1097/SLA.0b013e318153ff40 (DOI)18156935 (PubMedID)
Available from: 2008-12-04 Created: 2008-12-04 Last updated: 2017-12-14Bibliographically approved
Villman, K., Ståhl, E., Liljegren, G., Tidefelt, U. & Karlsson, M. G. (2002). Topoisomerase II-α expression in different cell cycle phases in fresh human breast carcinomas. Modern Pathology, 15(5), 486-491
Open this publication in new window or tab >>Topoisomerase II-α expression in different cell cycle phases in fresh human breast carcinomas
Show others...
2002 (English)In: Modern Pathology, ISSN 0893-3952, E-ISSN 1530-0285, Vol. 15, no 5, p. 486-491Article in journal (Refereed) Published
Abstract [en]

Topoisomerase II-alfa (topo IIalfa) is the key target enzyme for the topoisomerase inhibitor class of anti-cancer drugs. In normal cells, topo IIalfa is expressed predominantly in the S/G2/M phase of the cell cycle. In malignant cells, in vitro studies have indicated that the expression of topo IIalfa is both higher and less dependent on proliferation state in the cell. We studied fresh specimens from 50 cases of primary breast cancer. The expression of topo IIalfa in different cell cycle phases was analyzed with two-parameter flow cytometry using the monoclonal antibody SWT3D1 and propidium iodide staining. The expression of topo IIalfa was significantly higher in the S/G2/M phase of the cell cycle than in the G0/G1 phase in both DNA diploid and DNA nondiploid tumors. In 18 of 21 diploid tumors, and in 25 of 29 nondiploid tumors, >50% of the topo IIalfa–positive cells were in the G0/G1 phase. This significant expression of topo IIalfa in the G0/G1 phase of the cell cycle may have clinically important implications for treatment efficacy of topoisomerase II inhibitors.

Place, publisher, year, edition, pages
Baltimore: Lippincott Williams & Wilkins, 2002
Keywords
breast cancer, cell cycle, DNA flow cytometry, topoisomerase IIa
National Category
Medical and Health Sciences
Research subject
Medicine; Biomedicine
Identifiers
urn:nbn:se:oru:diva-10515 (URN)
Available from: 2010-04-27 Created: 2010-04-27 Last updated: 2017-12-12Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-8598-1773

Search in DiVA

Show all publications